Advancements in Multiple Sclerosis Research: Focus on Biomarkers and Aging
More than 20 disease-modifying therapies (DMTs) exist for MS. The 2024 McDonald criteria integrate advanced MRI biomarkers to facilitate earlier diagnosis. Aging affects disease pathology and treatment responses. Current monitoring tactics like relapses and MRI activity have drawbacks. Emerging biomarkers might enhance treatment decisions, but further validation is required.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These advancements signal progress in understanding MS and improving diagnosis and treatment strategies, addressing significant challenges in current practices.
What this does not prove
This review does not establish efficacy for treatment approaches and lacks specific study outcomes or data.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-30
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceManagement of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies. ↗DOI: 10.1007/s40265-026-02391-1
Supporting passages (7)
publication date2026-09-30
findingsMultiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system for which more than 20 disease-modifying therapies (DMTs) are currently available.
findingsThe 2024 McDonald diagnostic criteria expand the biological definition of MS through incorporation of advanced MRI biomarkers, thereby supporting earlier diagnosis and potentially earlier treatment initiation.
findingsAging influences both disease pathobiology and treatment risk-benefit balance, contributing to reduced focal inflammatory activity, increased progression, diminished regenerative capacity, and greater susceptibility to infections and comorbidities.
findingsCurrent monitoring strategies remain centered on relapses, disability measures, and MRI lesion activity, but each has important limitations.
findingsEmerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed.
limitationsTitle: Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.